nach oben

Archives of Virology

Erschienen in:

01.04.2011 | Original Article

Construction of a minigenome rescue system for Newcastle disease virus strain Italien

verfasst von: Hao Feng, Ding Wei, Gang Nan, Shang-Jin Cui, Zhi-Nan Chen, Huijie Bian

Erschienen in: Archives of Virology | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Newcastle disease virus (NDV) Italien, a velogenic strain, is an oncolytic virus that is considered to be a potential agent for antitumor viral therapy. We constructed three helper plasmids expressing the NP, P and L genes of NDV Italien based on the eukaryotic expression plasmid pcDNA3.1(+). The minigenome consisting of the 3′ leader and 5′ trailer regions of NDV Italien flanking a reporter gene encoding firefly luciferase was constructed to examine the efficacy of the three helper plasmids in viral genome replication and transcription. After co-transfection of BSR-T7/5 cells with the three helper plasmids and the minigenome plasmid, replication of minigenome RNA was evaluated by determining luciferase activity. In the minigenome rescue system, expression of the reporter gene was detected. Our results indicate that the three proteins NP, P, and L are correctly expressed and can assemble into a functional ribonucleoprotein complex that effectively directs the transcription of minigenome RNA.

Seal BS, King DJ, Sellers HS (2000) The avian response to Newcastle disease virus. Dev Comp Immunol 24(2–3):257–268PubMedCrossRef

Krishnamurthy S, Samal SK (1998) Nucleotide sequences of the trailer, nucleocapsid protein gene and intergenic regions of Newcastle disease virus strain Beaudette C and completion of the entire genome sequence. J Gen Virol 79(Pt 10):2419–2424PubMed

Nakaya T et al (2001) Recombinant Newcastle disease virus as a vaccine vector. J Virol 75(23):11868–11873PubMedCrossRef

Krishnamurthy S, Huang Z, Samal SK (2000) Recovery of a virulent strain of Newcastle disease virus from cloned cDNA: expression of a foreign gene results in growth retardation and attenuation. Virology 278(1):168–182PubMedCrossRef

Peeters BP et al (1999) Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence. J Virol 73(6):5001–5009PubMed

Kolakofsky D et al (1998) Paramyxovirus RNA synthesis and the requirement for hexamer genome length: the rule of six revisited. J Virol 72(2):891–899PubMed

Peeters BP et al (2000) Genome replication of Newcastle disease virus: involvement of the rule-of-six. Arch Virol 145(9):1829–1845PubMedCrossRef

Fiola C et al (2006) Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence. Int J Cancer 119(2):328–338PubMedCrossRef

Reichard KW et al (1992) Newcastle disease virus selectively kills human tumor cells. J Surg Res 52(5):448–453PubMedCrossRef

10.

Puhlmann J et al (2010) Rac1 is required for oncolytic NDV replication in human cancer cells and establishes a link between tumorigenesis and sensitivity to oncolytic virus. Oncogene 29(15):2205–2216PubMedCrossRef

11.

Bian H et al (2006) In vivo efficacy of systemic tumor targeting of a viral RNA vector with oncolytic properties using a bispecific adapter protein. Int J Oncol 29(6):1359–1369PubMed

12.

Lazar I et al (2009) The oncolytic activity of Newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis protein Livin. J Virol 84(1):639–646CrossRef

13.

Yaacov B et al (2008) Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors. Cancer Gene Ther 15(12):795–807PubMedCrossRef

14.

Lorence RM et al (2007) Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus. Curr Cancer Drug Targets 7(2):157–167PubMedCrossRef

15.

Freeman AI et al (2006) Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther 13(1):221–228PubMedCrossRef

16.

Lazar I et al (2010) The oncolytic activity of Newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis protein Livin. J Virol 84(1):639–646PubMedCrossRef

17.

Jiang Y et al (2009) Plasmids driven minigenome rescue system for Newcastle disease virus V4 strain. Mol Biol Rep 36(7):1909–1914PubMedCrossRef

18.

Buchholz UJ, Finke S, Conzelmann KK (1999) Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture and the human RSV leader region acts as a functional BRSV genome promoter. J Virol 73(1):251–259PubMed

19.

Altomonte J et al (2010) Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma. Mol Ther 18(2):275–284PubMedCrossRef

20.

Zamarin D et al (2009) Enhancement of oncolytic properties of recombinant Newcastle disease virus through antagonism of cellular innate immune responses. Mol Ther 17(4):697–706PubMedCrossRef

21.

Vigil A et al (2008) Recombinant Newcastle disease virus as a vaccine vector for cancer therapy. Mol Ther 16(11):1883–1890PubMedCrossRef

22.

Janke M et al (2008) Activation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2. Int J Oncol 33(4):823–832PubMed

23.

Puhler F et al (2008) Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes. Gene Ther 15(5):371–383PubMedCrossRef

24.

Freiberg A et al (2008) Establishment and characterization of plasmid-driven minigenome rescue systems for Nipah virus: RNA polymerase I- and T7-catalyzed generation of functional paramyxoviral RNA. Virology 370(1):33–44PubMedCrossRef

25.

de Wit E et al (2007) A reverse-genetics system for Influenza A virus using T7 RNA polymerase. J Gen Virol 88(Pt 4):1281–1287PubMedCrossRef

26.

Bailey D et al (2007) Reverse genetics for peste-des-petits-ruminants virus (PPRV): promoter and protein specificities. Virus Res 126(1–2):250–255PubMedCrossRef

27.

Yan Y et al (2009) Role of untranslated regions of the hemagglutinin-neuraminidase gene in replication and pathogenicity of Newcastle disease virus. J Virol 83(11):5943–5946PubMedCrossRef

28.

Wei D et al (2008) Characterization of the genome sequence of an oncolytic Newcastle disease virus strain Italien. Virus Res 135(2):312–319PubMedCrossRef

29.

Yue H et al (2009) Short hairpin RNA targeting NP mRNA inhibiting Newcastle disease virus production and other viral structural mRNA transcription. Virus Genes 38(1):143–148PubMedCrossRef

30.

Hasan MK et al (1997) Creation of an infectious recombinant Sendai virus expressing the firefly luciferase gene from the 3′ proximal first locus. J Gen Virol 78(Pt 11):2813–2820PubMed

31.

Wertz GW, Perepelitsa VP, Ball LA (1998) Gene rearrangement attenuates expression and lethality of a nonsegmented negative strand RNA virus. Proc Natl Acad Sci USA 95(7):3501–3506PubMedCrossRef

Titel: Construction of a minigenome rescue system for Newcastle disease virus strain Italien
verfasst von: Hao Feng
Ding Wei
Gang Nan
Shang-Jin Cui
Zhi-Nan Chen
Huijie Bian
Publikationsdatum: 01.04.2011
Verlag: Springer Vienna
Erschienen in: Archives of Virology / Ausgabe 4/2011
Print ISSN: 0304-8608
Elektronische ISSN: 1432-8798
DOI: https://doi.org/10.1007/s00705-010-0898-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Hereditäres Angioödem: Tablette könnte Akuttherapie erleichtern

05.06.2024 Hereditäres Angioödem Nachrichten

Medikamente zur Bedarfstherapie bei hereditärem Angioödem sind bisher nur als Injektionen und Infusionen verfügbar. Der Arzneistoff Sebetralstat kann oral verabreicht werden und liefert vielversprechende Daten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2011

Complete genomic sequence of virulent Cronobacter sakazakii phage ESSI-2 isolated from swine feces

Asialoglycoprotein receptor interacts with the preS1 domain of hepatitis B virus in vivo and in vitro

Development of a molecular-beacon-based multi-allelic real-time RT-PCR assay for the detection of human coronavirus causing severe acute respiratory syndrome (SARS-CoV): a general methodology for detecting rapidly mutating viruses

Molecular characterization and phylogenetic analysis of porcine epidemic diarrhea virus (PEDV) field isolates in Korea

Multiple amino acid variations in the nonstructural proteins of swine Japanese encephalitis virus alter its virulence in mice